Milestone Payment Amounts Sample Clauses

Milestone Payment Amounts. The Licensee will make a payment to CASE within thirty (30) days of each occurrence of the achievement of a Milestone as follows: MILESTONE MILESTONE PAYMENT AMOUNT […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…]) […***…] […***…] Dollars (U.S. $[…***…])
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Milestone Payment Amounts. Subject to Parent’s Right of Setoff pursuant to Article VII, upon a Subsequent Payment Date, Parent shall, within five (5) Business Days following its receipt of the Milestone Payment Allocation Notification, pay (i) to each Equityholder who has complied with the procedures set forth in this Section 2.9 each such Equityholder’s portion of the Milestone Payment Amount payable upon achievement of the applicable Milestone and as set forth opposite such Equityholder’s name on the original Closing Date Allocation Schedule or the Future Payment Allocation Schedule delivered by the Equityholders’ Representative pursuant to Section 8.1(h), and (ii) to Stifel the Stifel Payment Amounts set forth on such Closing Date Allocation Schedule or Future Payment Allocation Schedule, in each case in immediately available funds by check or by wire transfer to such bank account or accounts as may be specified on such Closing Date Allocation Schedule or Future Payment Allocation Schedule. Notwithstanding anything in this Agreement to the contrary, in the event that any of the Second Subsequent Payment Date, Third Subsequent Payment Date or Fourth Subsequent Payment Date occurs and prior to such time, any earlier Milestone has not been achieved and thus its corresponding Subsequent Payment Date has not occurred and/or Milestone Payment Amount has not been paid (“Unpaid Milestones”), any such Unpaid Milestone shall be deemed to be achieved upon the achievement of such later Milestone and the applicable Milestone Payment Amounts shall all become payable upon the later Subsequent Payment Date; provided, however, that in the event that a New Drug Application has been submitted to the FDA prior to the initiation of the pivotal efficacy study contemplated by the First Milestone, then the First Milestone shall only become payable upon the earlier of achievement of the First Milestone or the achievement of the Third Milestone.
Sample 1
Milestone Payment Amounts. The Sublicensee will make a one-time payment on a Licensed Product by Licensed Product basis to NeoIndicate within thirty (30) days of each occurrence of the achievement of a Milestone as follows: (a) Diagnostic Licensed Product Milestone Payments: DIAGNOSTIC LICENSED PRODUCT(S) MILESTONE MILESTONE PAYMENT AMOUNT eIND or IND Diagnostic approval $ 75,000 First dose of Diagnostic in Phase I anywhere in world $ 75,000 First dose of Diagnostic in Phase II anywhere in world $ 150,000 First dose of Diagnostic in Phase III anywhere in world $ 300,000 US FDA Regulatory Approval Diagnostic $ 1,000,000 Outside of US Regulatory Approval Diagnostic $ 500,000 Upon first reaching cumulative aggregate gross sales of $25M Diagnostic $ 750,000 Upon first reaching cumulative aggregate gross sales of $100M Diagnostic $ 3,000,000 Upon first reaching cumulative aggregate gross sales of $250M Diagnostic $ 7,500,000 Upon first reaching cumulative aggregate gross sales of $500M Diagnostic $ 15,000,000 Upon first reaching cumulative aggregate gross sales of $1 Billion Diagnostic $ 30,000,000 Upon first reaching cumulative aggregate gross sales of $2 Billion Diagnostic $ 60,000,000 (b) Therapeutic Licensed Product Milestone Payments: THERAPEUTIC LICENSED PRODUCT(S) MILESTONE MILESTONE PAYMENT AMOUNT eIND or IND approval of therapeutic $ 100,000 First dosing Therapeutic of patients in Phase I anywhere in world $ 100,000 First dosing Therapeutic of patients in Phase II anywhere in world $ 200,000 First dosing Therapeutic of patients in Phase III anywhere in world $ 500,000 US FDA Approval Therapeutic $ 2,000,000 Outside of US Regulatory Approval Therapeutic $ 1,000,000 Upon first reaching cumulative aggregate gross sales of $25M Therapeutic $ 1,000,000 Upon first reaching cumulative aggregate gross sales of $100M Therapeutic $ 5,000,000 Upon first reaching cumulative aggregate gross sales of $250M Therapeutic $ 10,000,000 Upon first reaching cumulative aggregate gross sales of $500M Therapeutic $ 20,000,000 Upon first reaching cumulative aggregate gross sales of $1 Billion Therapeutic $ 40,000,000 Upon first reaching cumulative aggregate gross sales of $2 Billion Therapeutic $ 80,000,000 This Section shall be construed as requiring separate Milestone payments for each and every Licensed Product that is subject to a Clinical Trial, Regulatory Approval, and/or Product Launch and shall not be construed as limiting the number of times each Milestone can be achieved and for which payment ...
Sample 1
Milestone Payment Amounts. The Licensee will make a payment to CWRU within thirty (30) days of each occurrence of the achievement of a Milestone as follows: MILESTONE MILESTONE PAYMENT AMOUNT <INITIATE/COMPLETE> Phase I Clinical Trial $ <FEE> and <NUMBER> shares of Common Stock <INITIATE/COMPLETE> Phase II Clinical Trial $<FEE> and <NUMBER> shares of Common Stock <INITIATE/COMPLETE> Phase III Clinical Trial $<FEE> and <NUMBER> shares of Common Stock BLA Approval $<FEE> and <NUMBER> shares of Common Stock Product Launch $<FEE> and <NUMBER> shares of Common Stock This Section shall be construed as requiring separate Milestone payments for each and every Licensed Product that is subject to a Clinical Trial, BLA Approval and/or Product Launch and shall not be construed as limiting the number of times each Milestone can be achieved and for which payment is required. For example, $<FEE> and <NUMBER> shares of Common Stock shall be paid to CWRU for each Phase I Clinical Trial that is initiated.
Sample 1
Milestone Payment Amounts. The Licensee will make a payment to CASE within thirty (30) days of each occurrence of the achievement of a Milestone as follows: MILESTONE MILESTONE PAYMENT AMOUNT [*]. [*] Dollars (U.S. [*]) [*]. [*] Dollars (U.S. $[*]) [*]. [*] Dollars (U.S. [*]) [*] [*] Dollars (U.S. [*]) [*]. [*] Dollars (U.S. $[*]) [*]. [*] Dollars (U.S. $[*]) [*]. [*] Dollars (U.S. $[*]) [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. [*]. [*] Dollars (U.S. $[*]) [*]. [*] Dollars (U.S. $[*]) [*]. [*] Dollars (U.S. $[*]) [*]. [*] Dollars (U.S. $[*]) [*]. [*] Dollars (U.S. $[*]) [*]. [*] Dollars (U.S. $[*]) For purposes of this Section 5.5, a Combination Therapeutic will be deemed a second or third Combination Therapeutic if the therapeutic compound(s) comprising the additional formulation(s) (other than methoxyamine or a methoxyamine derivative) included in such Combination Therapeutic are not included in the Combination Therapeutic(s) that were the subject of an NDA or application for Disposition, as applicable, previously approved by the applicable regulatory body (i.e., are not included in the Combination Therapeutic(s) that triggered the preceding Milestone(s)).”
Sample 1
Milestone Payment Amounts. The Licensee will make a payment to CWRU within thirty (30) days of the occurrence of the achievement of a Milestone in spinal cord injury or peripheral nerve injury as follows: MILESTONE MILESTONE PAYMENT AMOUNT First Dosing in a Phase I Clinical Trial [DOLLAR AMOUNT REDACTED ] First Dosing in a Phase II Clinical Trial [DOLLAR AMOUNT REDACTED] First Dosing in a Phase III Clinical Trial [DOLLAR AMOUNT REDACTED] FDA Approval and First Commercial Sale in USA [DOLLAR AMOUNT REDACTED] Regulatory Approval and First Commercial Sale outside the USA [DOLLAR AMOUNT REDACTED ] For the first and second Licensed Product that achieves a milestones set forth above in an Indication which is not spinal cord injury or peripheral nerve injury, the Licensee will make a payment to CWRU within thirty (30) days of the occurrence of the achievement of a Milestone at a rate which is [PERCENTAGE REDACTED] of the Milestone Payment Amount(s) listed above.
Sample 1

Related to Milestone Payment Amounts

  • Milestone Payment The first time Net Sales in the Territory in a Royalty Period exceed US$[***] ([***] dollars) US$[***] ([***] dollars)

  • Sales Milestone Payments Artiva shall make the following one-time, non-refundable and non-creditable sales milestone payments to GCLC when the aggregate annual Net Sales of Products in the Territory first reach the thresholds specified below. Artiva shall notify GCLC promptly of the achievement of each such sales threshold. Each sales milestone payment shall be made by Artiva within [***] days after the end of the calendar quarter in which such sales threshold is achieved. To the extent more than one sales threshold is reached in any given calendar year, then the applicable milestone payment for each such achievement shall be due and owing with respect to such calendar year. For clarification, the total milestone payments payable hereunder if all milestone events are achieved is [***].

  • Milestone Payments In the event that any Sellers believe that any Additional Milestone has been achieved during the Post-Closing Milestone Period, the Sellers’ Representative shall provide notice of such achievement to Purchaser. If Purchaser determines in its sole and reasonable discretion that such Additional Milestone has been achieved during the Post-Closing Milestone Period, then within thirty (30) days of such notice from Sellers’ Representative or, if earlier, within thirty (30) days of Purchaser’s determination that such Additional Milestone has been achieved, Purchaser shall notify Sellers’ Representative of its determination and pay to Sellers the Additional Milestone Payment payable in respect of such Additional Milestone. If Sellers’ Representative delivers such a notice and Purchaser determines, in its sole and reasonable discretion, that the applicable Additional Milestone has not been achieved, then, within thirty (30) days of Sellers’ Representative’s notice Purchaser shall notify Sellers’ Representative of such determination. If Sellers’ Representative believes that Sellers are entitled to payment of all or any portion of an Additional Milestone Payment hereunder which they have not received within thirty (30) days following the achievement of the Additional Milestone for which payment is due, Sellers’ Representative may, not later than twelve (12) months following the achievement of such Additional Milestone, deliver to Purchaser a notice setting forth Sellers’ Representative’s determination that all or a portion of such Additional Milestone Payment is due under this Agreement (the “Post-Closing Assessment Notice”). If Sellers’ Representative does not deliver to Purchaser a Post-Closing Assessment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. Notice within such twelve (12) month period, then Sellers shall have been deemed to agree that the Additional Milestone has not been met and no payment with respect to such Additional Milestone is due to Sellers hereunder and Sellers shall have no further rights to such Milestone Payment or any portion thereof. Such Post-Closing Assessment Notice may be delivered before or after the expiration of the Post-Closing Milestone Period without affecting Sellers’ rights to the applicable Milestone Payment, provided that that applicable Additional Milestone was actually achieved prior to the expiration of such Post-Closing Milestone Period. If Purchaser shall object to Sellers’ determination that a Additional Milestone has been achieved as set forth in the Post-Closing Assessment Notice, then Purchaser shall deliver a dispute notice (a “Post-Closing Milestone Dispute Notice”) to Sellers’ Representative within fifteen (15) days following Sellers’ Representative’s delivery of the Post-Closing Assessment Notice. A representative of Purchaser, on the one hand, and the Sellers’ Representative, on the other, shall attempt in good faith to resolve any such objections within fifteen (15) days of the receipt by Sellers of the Post-Closing Milestone Dispute Notice. If no Post-Closing Milestone Dispute Notice is delivered within the fifteen (15) day time period, then Sellers’ determination that the Additional Milestone has been achieved, and that the amount of the Milestone Payment specified in the Post-Closing Milestone Dispute Notice is due hereunder, shall be deemed to be accepted and Purchaser shall pay to Sellers those amounts set forth in the Post-Closing Assessment Notice no later than five (5) days after the expiration of such fifteen (15) day time period.

  • Development Milestone Payments (i) In addition to the Closing Date Merger Consideration (less the Remaining Option Consideration and Rights Proceeds Amount, if any) and any Net TNF Sales Payments (as defined below), upon the attainment of the development ** Portions of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. milestones set forth below (each, a “Development Milestone”), Parent shall, or shall cause the Surviving Corporation to, [**] after the occurrence of each Development Milestone, deliver to the Paying Agent (for further payment to the holders of Stock Certificates and Stock Agreements outstanding immediately prior to the Effective Time), via wire transfer of immediately available funds, the respective amounts set forth below minus, in each case, the applicable Contingent Consideration Distribution Fee associated therewith and any amount designated by the Stockholders’ Representatives to be placed in the Administrative Expense Account (each, a “Development Milestone Payment” and collectively, the “Development Milestone Payments”): (A) Upon FDA approval of Reslizumab for the treatment of eosinophilic esophagitis, a cash payment of [**]; (B) Upon marketing authorization of Reslizumab for the treatment of eosinophilic esophagitis being granted by the European Commission in accordance with Regulation (EC) No. 726/2004, a cash payment of [**]; (C) If Res 5-0010 Asthma Study Completion has not occurred on or prior to the Closing Date, then upon the occurrence of the Res 5-0010 Asthma Study Completion, a cash payment of $50,000,000 (fifty million dollars) (the “Res 5-0010 Asthma Payment”); (D) Upon FDA approval of Reslizumab for any asthma indication, a cash payment of [**]; (E) Upon marketing authorization of Reslizumab for the treatment of any asthma indication being granted by the European Commission in accordance with Regulation (EC) No. 726/2004, a cash payment of [**]; and (F) Upon FDA approval of an Oral Anti-TNF Product, a cash payment of [**].

  • Milestone Fees Licensee will pay Milestone Fees indicated in Section 3.1(b) of the Patent & Technology License Agreement by the Quarterly Payment Deadline for the Contract Quarter in which the milestone events set forth in Section 3.1(b) of the Patent & Technology License Agreement are achieved.

  • Milestone Event Milestone Payment [***] [***]

  • Milestone A principal event specified in the Contract Documents including the Material Completion and Occupancy Date and other events relating to an intermediate completion date or time.

  • Payment Amounts The aggregate Payments to be made in any fiscal year shall not exceed an amount that is equal to the corresponding Appropriated Amount. (For example, for the Payments due on December 1, 2022 and on June 1, 2023, the aggregate maximum amount of such Payments would be determined by the Appropriated Amount determined for certification by December 1, 2021.) Furthermore, the amount of each such Payment shall not exceed the amount of Incremental Property Tax Revenues (excluding allocations of “back-fill” or “make-up” (payments from the State of Iowa for property tax credits or roll-back) actually received by the City from the Dubuque County Treasurer attributable to the taxable incremental valuation of the Property in the six (6) months immediately preceding the extant Payment due date.

  • Sales Milestones (a) As to each Therapeutic Product, SANOFI-AVENTIS shall pay MERRIMACK up to a total of Sixty Million Dollars (US$60,000,000) upon the first achievement of the following Net Sales milestones, on a Therapeutic Product-by-Therapeutic Product basis: (i) Total Worldwide Net Sales for such Therapeutic Product exceed $[**] in any four (4) consecutive calendar quarters $ [**] (ii) Total Worldwide Net Sales for such Therapeutic Product exceed $[**] in any four (4) consecutive calendar quarters $ [**] (iii) Total Worldwide Net Sales for Therapeutic Product exceed $[**] in any four (4) consecutive calendar quarters $ [**] (b) Each milestone payment set forth in Section 8.4(a) shall be payable by SANOFI-AVENTIS upon the achievement of the related milestone event by SANOFI-AVENTIS and its Affiliates or sublicensees, and SANOFI-AVENTIS shall provide notice to MERRIMACK promptly upon achievement of such milestone event. SANOFI-AVENTIS shall pay MERRIMACK each such milestone payment within [**] days of such achievement of the related milestone event. (c) For purposes of clarity, more than one of the Net Sales milestones set forth above may be earned in the same four (4) consecutive calendar quarter period with respect to a Therapeutic Product. For example, if total worldwide Net Sales with respect to a given Therapeutic Product have not achieved any of the lower sales milestone thresholds set forth in clause (i) or (ii) of Section 8.3(a) above in any previous four (4) consecutive calendar quarter period, but total worldwide Net Sales with respect to such Therapeutic Product exceed $[**] in a subsequent four (4) consecutive calendar quarter period, then all three milestone payments, totaling $60 Million, payable upon achievement of the sales milestone thresholds set forth in clause (i), (ii) and (iii) of Section 8.3(a) above shall become payable to MERRIMACK hereunder.

  • Milestones Subject to the provisions of the SGIP, the Parties shall agree on milestones for which each Party is responsible and list them in Attachment 4 of this Agreement. A Party’s obligations under this provision may be extended by agreement. If a Party anticipates that it will be unable to meet a milestone for any reason other than a Force Majeure event, it shall immediately notify the other Parties of the reason(s) for not meeting the milestone and (1) propose the earliest reasonable alternate date by which it can attain this and future milestones, and (2) requesting appropriate amendments to Attachment 4. The Party affected by the failure to meet a milestone shall not unreasonably withhold agreement to such an amendment unless it will suffer significant uncompensated economic or operational harm from the delay, (1) attainment of the same milestone has previously been delayed, or (2) it has reason to believe that the delay in meeting the milestone is intentional or unwarranted notwithstanding the circumstances explained by the Party proposing the amendment.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!